Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

NCT04656951 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT04656951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04656951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
Lead sponsor
University of Cologne
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 1, 2021
Completion date
December 31, 2031
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma